Diabetes & Heart Failure Treatment Study

The EMMED-HF Study: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure

Abstract plexus heart
AGE: 18 – 75 years old
GENDER: All
HEALTHY PARTICIPANTS: No
TYPE: Interventional Study
CONDITION: Heart Disease, Diabetes
LOCATION: University Hospitals Cleveland Medical Center

Learn More About This Research Study

For more information, please contact Ann Dever at 216-286-5038 and leave a message or complete the online form below.

Study Purpose

The purpose of this research this study is to investigate the effectiveness of ertugliflozin (a pill that lowers glucose levels) therapy to alter the heart’s metabolism to positively impact heart health and function in treating subjects with a type of chronic (long term) heart failure (HF) called heart failure with preserved ejection fraction (HFpEF).

Who Can Participate

Individuals between 18 and 75 years old who have not been hospitalized for heart failure within 6 months and has a BMI greater than 29 but less than 42 may be eligible for this study.

Request More Information

To learn more about this study, please fill out the form below to request more information.

XXX-XXX-XXXX

StudyID: